BalanceSense, LLC Awards StudyManager Phase II Study for Returning Troops with Mild-Trauma Brain Injury
StudyManager
announced that
BalanceSense, LLC
awarded StudyManager an eight-site, Phase II Army contract to implement Evolve CTMS and EDC.
BalanceSense sought a flexible, easy to use solution for the management of clinical data captured by physical therapists treating returning troops with mild-trauma brain injuries, and to centralize, track, and manage study progress.
“We are pleased to have the opportunity to contribute to this important effort in working with Dr. Karen Atkins, PhD, PT, Balance Sense, LLC and her team,” said Sue Blecman, Vice President of Sales, StudyManager. “It’s a privilege for StudyManager and Evolve to have been selected as one of BalanceSense’s civilian partners to support much needed treatment for our returning troops. We look forward to their clinical and operational success with this study.”
Evolve's web-based interface integrates clinical trial management and electronic data capture tools. These features are very scalable, and can be used together seamlessly or independently. Evolve enables users to create a single, centralized and secure location for key study information, simplifying study operations and enhancing team efficiency.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
